Biotech · Private company
Senju Pharmaceutical Co., Ltd.
Track this companyFree. Adds Senju Pharmaceutical Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- SJP-0035 0.001%Phase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- High Dose SJP-0035 Ophthalmic SolutionPhase 2 · Corneal Epithelial DisordersClinicalTrials.gov · fetched Nov 12, 2026
- Low Dose SJP-0035 Ophthalmic SolutionPhase 2 · Corneal Epithelial DisordersClinicalTrials.gov · fetched Nov 12, 2026
- MT-0814Phase 2 · Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- SJP-0035 Ophthalmic SolutionPhase 2 · Corneal Epithelial DisordersClinicalTrials.gov · fetched Nov 12, 2026
- SJP-0132Phase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle of SJP-0035 Ophthalmic solutionPhase 2 · Corneal Epithelial DisordersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye DiseasePHASE1_PHASE2 · COMPLETED · started Oct 5, 2019ClinicalTrials.gov NCT04139122 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular DegenerationPHASE2 · TERMINATED · started Feb 25, 2019ClinicalTrials.gov NCT03869684 · fetched Nov 12, 2026
- A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye DiseasePHASE3 · COMPLETED · started Aug 20, 2018ClinicalTrials.gov NCT03527212 · fetched Nov 12, 2026
- Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial DisordersPHASE2 · COMPLETED · started Sep 1, 2016ClinicalTrials.gov NCT02929823 · fetched Nov 12, 2026
- Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial DisordersPHASE2 · COMPLETED · started Apr 8, 2014ClinicalTrials.gov NCT02104388 · fetched Nov 12, 2026